Wyeth

Genetics Institute, Inc.

Virginia Polytechnic Institute and State University

Other

James C Keith, Jr

Heather Anne Harris

Leo M Albert

Michael David Collini

Christopher P Miller

Michael Sotirios Malamas

Iwan Suwandi Gunawan

Eric Steven Manas

Richard Eric Mewshaw

Robert E McDevitt

Paul F Schendel

Richard J Edsall

Camille L Bedrosian

Rayomand Jal Unwalla

John W Ullrich

Robert L Morris

Robert R Singhaus, Jr

David H Kaufman

Cuijian Yang

Nick W Warne

Ullrich S Schwertschlag

Gary S Gray

William Floyd Fobare

Stephen Todd Cohn

Nicholas W Warne

Sreenivasulu Megati

Galina Vid

Richard Dale Coghlan

C Richard Lyttle

Vincent Ling

Ullrich S Schwerschlag

Cecil Richard Lyttle

Folake O Adebi

Tam Q Dinh

G Van Asche

Inge Depoortere

Theo L Peeters

Srinivas Maganti

This invention provides estrogen receptor modulators of formula I, having the structure whereinR, R, R, R, R, and R, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

Substituted benzoxazoles as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structure wherein, 

6-Hydroxyequilenins as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structure wherein R, R, R, R, R, and R, and X as defined in the specification, or a pharmaceutically acceptable salt thereof.

This invention provides estrogen receptor modulators of formula I, having the structure wherein

Substituted phenyl naphthalenes as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structurewherein

Substituted 2-phenyl benzofurans as estrogenic agents

Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structureR, R, and Rare as defined in the specification, or a pharmaceutically acceptable salt thereof.

Substituted indenones as estrogenic agents

Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e.g., conjunctivitis, retinitis, and uveitis).

Method of using IL-11 for treating mucositis

This invention provides estrogen receptor modulators of formula I, having the structurewherein,

Phenyl benzisoxazoles as estrogenic agents

Phenyl substituted thiophenes as estrogenic agents

Substituted 6H-DiBenzo&lsqb;c,h&rsqb;chromenes as estrogenic agents

The use of interleukin-11 to prevent, to ameliorate, and to treat a gastrointestinal disorder in a mammal in need of such treatment is disclosed.

Use of interleukin-11 to treat gastrointestinal disorders

Methods of inhibiting and diagnosing spontaneous abortion in a subject are provided. The subject methods are based, inter alia, on the administration of an agent that inhibits a CD28-C mediated costimulatory signal in a T cell such that spontaneous abortion in the subject is inhibited. The subject methods are also based on the levels of adhesion molecules, inflammatory cytokines, and immune cell surface molecules which are altered in spontaneous abortion.

Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal

Growing community of inventors

Andover, MA, United States of America

James C Keith, Jr